BioSpace News Archive

Artelo Biosciences, Inc. announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually May 16th - 20th, 2022.

Edesa Biotech, Inc. reported financial results for the three and six months ended March 31, 2022 and provided an update on its business.

Ceapro Inc. announced that Bernhard Seifried, Ph.D., Ceapro’s Senior Director, Research & Technology, will give a keynote lecture titled, Aerogels & Composites: From Concept to Applications, at the 13th International Symposium on Supercritical Fluids being held May 15-18, 2022 in Montréal, Québec, Canada.

ReviR Therapeutics announced the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.

RaySearch Laboratories AB releases preliminary figures for the first quarter of 2022. Order intake increases by 88 percent to SEK 273 million, sales increase by 28 percent to SEK 208 million and EBIT amounts to SEK 29 million.

Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2 Inflammatory specialty diseases, today announced that it will present a poster demonstrating the ability of LNR 125.38 (“LNR125”) to inhibit Type 2 inflammation in models of asthma caused by both allergy and respiratory viral infection at the upcoming American Thoracic Society Meeting.

The Anesthesia & Respiratory Devices market size is expected to hit around US$ 50.4 billion by 2028 and is projected to grow at a CAGR of 7.6% during forecast period 2021 to 2028.

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, May 17, 2022, to discuss the company’s financial results for the first quarter ended March 31, 2022.

The Bariatric Surgery Devices market was valued at US$ 12.3 billion in 2020 and is expected to hit around US$ 12.8 billion by 2030 with a CAGR of 20.15% during forecast period 2021 to 2030.

Use of drug discovery software for gaining market intelligence owing to several advantages, such as rapid drug design & synthesis, efficient tracking of disease evolution, and data integrity management, has increased significantly among the researchers in the recent years, driving the industry growth.